AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pumbwe, L.
Right arrow Articles by Wexler, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pumbwe, L.
Right arrow Articles by Wexler, H. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2006, p. 3150-3153, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00141-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

Efflux Pump Overexpression in Multiple-Antibiotic-Resistant Mutants of Bacteroides fragilis

Lilian Pumbwe,1,2 Daniel Glass,2 and Hannah M. Wexler1,2*

Greater Los Angeles Veterans Administration Healthcare Systems,1 Department of Medicine, University of California, Los Angeles, Los Angeles, California2

Received 2 February 2006/ Returned for modification 13 April 2006/ Accepted 12 June 1006


   ABSTRACT
Top
 Abstract
Text
 References
 
Multidrug-resistant mutants of a wild-type Bacteroides fragilis strain (strain ADB77) and a quadruple resistance nodulation division family efflux pump deletion mutant (ADB77 {Delta}bmeB1 {Delta}bmeB3 {Delta}bmeB12 {Delta}bmeB15) were selected with antimicrobials. Ampicillin, doripenem, imipenem, levofloxacin, and metronidazole selected for mutants from both strains; cefoxitin selected for mutants from strain ADB77 only; and sodium dodecyl sulfate selected mutants from ADB77{Delta}bmeB1 {Delta}bmeB3 {Delta}bmeB12 {Delta}bmeB15 only. The mutants overexpressed one or more efflux pumps.


   TEXT
Top
 Abstract
 Text
References
 
Bacteroides fragilis is a clinically significant bacterium well endowed with efflux pumps, including 16 efflux pumps (BmeB1 to Bme16) from the resistance nodulation division (RND) family. BmeB is the efflux pump component of the BmeABC tripartite efflux system, which comprises an efflux pump (BmeB), a membrane fusion protein (BmeA), and an outer membrane channel protein (BmeC) (7, 13). Expression of the efflux pumps of the RND family is prevalent in wild-type strains of B. fragilis, and these pumps transport several structurally unrelated antimicrobials (7, 13). Studies have demonstrated that antimicrobials can select for bacterial multidrug resistance (MDR) due to overexpression of the RND family of efflux pumps (3, 4, 5, 8). The aim of this study was to determine the potentials of various antimicrobials to select MDR mutants of B. fragilis that overexpress bmeB efflux pumps and to determine whether the absence of several bmeB genes would affect this selection.

The parent strains used in this study were B. fragilis ADB77 (Wadsworth Anaerobe Laboratory [WAL] strain 108), an isogen of B. fragilis 638R optimized for gene deletion, and its derivative, a quadruple bmeB deletion mutant, ADB77 {Delta}bmeB1 {Delta}bmeB3 {Delta}bmeB12 {Delta}bmeB15 (WAL 219) (7). Antimicrobial MICs for each strain were determined with the spiral gradient endpoint method (14). Mutants were selected from the strains described above by the spiral plater technique (9) in a single step on a gradient of increasing antimicrobial concentrations on brucella blood agar plates. Twenty-one antimicrobials (antibiotics, detergents, and dyes) were tested: ampicillin (AMP), cefoperazone, cefotaxime, ceftizoxime, cephalexin, chloramphenicol, ciprofloxacin, clindamycin, doripenem (DPM), faropenem (FPM), gatifloxacin, imipenem (IPM), levofloxacin (LVX), meropenem, metronidazole (MDZ), moxifloxacin, norfloxacin, tetracycline, ethidium bromide (ETBR), sodium dodecyl sulfate (SDS), and triclosan. The antimicrobials were deposited in a radially decreasing concentration gradient from the center to the outside of the plate by using a spiral plater (Autoplate 4000; Advanced Instruments, Norwood, MA). The strains were resuspended in brucella broth to an optical density equivalent to the 0.5 McFarland turbidity standard (108 CFU/ml) and were inoculated along the antimicrobial concentration gradient. The assay plates were incubated for 12 to 24 h at 37°C under anaerobic conditions. The bacteria grew from the edge of the plate toward the center. The end radius (ER) where growth stopped was the MIC. Susceptibility studies were performed on at least three independent occasions. A fourfold or greater difference in susceptibility was considered significant. The effects of efflux pump inhibitors (EPIs) were determined by measuring the decrease in antimicrobial MICs after incorporation of 25 µg/ml carbonyl cyanide m-chlorophenylhydrazone (CCCP) or reserpine (RPN).

Incubation of the MIC assay plates for 48 to 60 h resulted in isolated mutant colonies growing as a tail beyond the MIC up the concentration gradient to the tail end radius (TER) (Fig. 1). Five of 21 antimicrobials, ampicillin, doripenem, imipenem, meteronidazole, and levofloxacin, selected mutants from both strains (strains 108-AMP, 108-DPM, 108-IPM, 108-MDZ, 108-LVX 219-AMP, 219-DPM, 219-IPM, 219-MDZ, and 219-LVX); cefoxitin (FOX) selected a mutant from the wild type only (strain 108-FOX), and SDS selected a mutant from the deletion mutant only (strain 219-SDS). All mutants were resistant to at least three antimicrobial classes and were therefore multidrug resistant (Table 1). The MDR antibiograms varied between the mutants and were stable even after repeated subculture on antibiotic-free medium (MIC data were reproducible between three independent experiments). The selection of MDR mutants by SDS was particularly intriguing, especially since SDS is a fairly ubiquitous component of normal household and cosmetic cleansers. A correlation between the use of antiseptics/disinfectants and antibiotic resistance (11) has been reported, and triclosan has been shown to select for MDR mutants in Stenotrophomonas maltophilia (10). However, to our knowledge this is the first study demonstrating the selection of MDR mutants by a detergent. Due to the sheer number of antimicrobials used and the mutants selected, only antibiotics that selected mutants were used as representatives to determine the effects of EPIs on MICs. Studies usually show two- to fourfold effects of EPIs on MICs (6). In the current study, both EPIs reduced the MICs of the antimicrobials tested (ampicillin, cefoxitin, doripenem, imipenem, levofloxacin, metronidazole, norfloxacin, and SDS; P < 0.05) by up to fourfold, suggesting that energy-dependent efflux was a major mechanism of resistance in the MDR mutants selected (Table 1).


Figure 1
View larger version (90K):
[in this window]
[in a new window]
  		FIG. 1. Mutant selection with metronidazole by the spiral plater technique. (A) Locations 1 and 2, the wild-type strain (strain ADB77) that gave rise to mutants; locations 3 and 4, strain ADB77 {Delta}bmeB1 {Delta}bmeB3 {Delta}bmeB12 {Delta}bmeB15 that gave rise to mutants; location 5, metronidazole-resistant control strain; (B) enlargement of location 2. Colonies arose within the region (indicated by the white arrow, which also shows the increasing antibiotic concentration) between the endpoint radius (MIC) to the tail end radius (indicated by the two white lines).

 

View this table:
[in this window]
[in a new window]
  		TABLE 1. Antimicrobial susceptibilities of selected mutants

 
Total cellular RNA was isolated with an RNeasy Protect kit (QIAGEN, Valencia, CA). Gene expression was quantified by comparative quantitative real-time reverse transcription-PCR (RT-PCR) with a Quantitect SYBR green one-step RT-PCR kit (QIAGEN, Valencia, CA) and a SmartCycler instrument (Cepheid, Sunnyvale, CA). Primers amplified 130- to 170-bp products of the genes bmeB1 to bme16 (7). Final amounts of 250 ng of RNA were converted to cDNA, and the reactions were normalized with 16S rRNA. Expression was quantified by measuring changes in PCR cycle threshold (CT) values of the parental versus mutant strains using the delta-delta CT ({Delta}{Delta}CT) method (7, 12). Data from five experiments were analyzed by Student's t test, and a P value of ≤0.05 was considered significant. A twofold or greater difference in expression was considered different.

All mutants except for 219-DPM overexpressed one or more of the bmeB genes by greater than twofold (Table 2). Changes were detected in 11 of 16 bmeB genes (bmeB1, bmeB2, bmeB3, bmeB4, bmeB5, bmeB6, bmeB7, bmeB11, bmeB12, bmeB15, bmeB16). The order of the greatest fold overexpression was bmeB4 (14.9-fold), bmeB7 (14.0-fold), bmeB15 (9.1-fold), bmeB11 (7.9-fold), bmeB5 (6.3-fold), bmeB6 (6.2-fold), bmeB16 (4.3-fold), bmeB1 (4.2-fold), bmeB3 (3.7-fold), bmeB2 (3.2-fold), and bmeB12 (2.4-fold). The order of frequency of overexpression (the number of isolates in which the pump was overexpressed) was bmeB4 (six isolates); bmeB1 (five isolates); bmeB2, bmeB5, bmeB7, and bmeB11 (four isolates each); bmeB3, bmeB6, and bmeB12 (two isolates each); and bmeB15 and bmeB16 (one isolate each). A large number of publications on gene expression coupled with physiological data have shown that changes in gene expression as low as twofold can have a significant physiological impact, and real-time RT-PCR is a highly sensitive method which has been extensively used to study the differential expression of efflux pumps (2, 12). Therefore, the changes observed in this study were significant.


View this table:
[in this window]
[in a new window]
  		TABLE 2. Efflux pump overexpression in mutants selected from strain 108 (ADB77) and its derivative bmeB quadruple deletion mutant 219 (ADB77 {Delta}bmeB1 {Delta}bmeB3 {Delta}bmeB12 {Delta}bmeB15)

 
No mutations in the gyrA quinolone resistance-determining region were observed in any of the mutants, including the mutants selected with levofloxacin. Mutants were also beta-lactamase negative, as determined by the nitrocefin test.

In summary, antimicrobials can select for MDR mutants that overexpress bmeB genes; overexpression of particular bmeB genes is associated with certain MDR antibiograms. When several bmeB genes are missing (i.e., in strain 219), the mutant selection potential of antimicrobials is unchanged, reduced, or increased. Mutant 219-DPM did not overexpress any bmeB pumps and yet had an MDR profile which was affected by EPIs. In addition, mutants 219-LVX and 219-SDS overexpressed bmeB4 only but had high-level MDR profiles which differed slightly. These data suggest that a non-RND efflux gene(s) is also overexpressed, especially when several RND pumps are missing.

In conclusion, the mutant selection window (MSW) hypothesis postulates that bacterial mutant subpopulations resistant to antimicrobials are selected predominantly when drug concentrations are above the MIC but below the mutant prevention concentration (MPC; i.e., the lowest concentration where further mutant selection is prevented) (1, 15). In this study, the ER represented the MIC and the TER represented the MPC, and mutants were selected as a tail in the window between these concentrations. Therefore, these data support the MSW hypothesis. A recent animal model study of infection demonstrated that levofloxacin-resistant mutants of Staphylococcus aureus were most readily selected when antimicrobial concentrations at the site of infection fluctuated within the MSW defined in vitro (J. Cui, Y. Liu, W. Tong, K. Drlica, and X. Zhao, Abstr. 45th Intersci. Conf. Antimicrob. Agents Chemother., abstr. 431, 2005). Since several of the agents tested in our study are used in therapy for infections involving B. fragilis and our own studies have also demonstrated overexpression of bmeB efflux pump genes in clinical isolates of B. fragilis (7a), the data presented here could reflect a mechanism by which multidrug resistant isolates could arise during therapy.


   ACKNOWLEDGMENTS
 
This study was supported by Merit Review Funds from the U.S. Department of Veterans Affairs.

B. fragilis ADB77 (WAL 108) and pADB242, a plasmid used to construct WAL 219, were kind gifts from Michael Malamy, Tufts University Medical School, Boston, MA.


   FOOTNOTES
 
* Corresponding author. Mailing address: Wadsworth Anaerobe Laboratory, School of Medicine, University of California, Los Angeles, Bldg. 304, Room E3-224, GLAVAHCS 691/151J, Los Angeles, CA 90073. Phone: (310) 268-3404. Fax: (310) 268-4458. E-mail: hwexler{at}ucla.edu. Back


   REFERENCES
Top
 Abstract
 Text
 References
 

  1. Drlica, K. 2003. The mutant selection window and antimicrobial resistance. J. Antimicrob. Chemother. 52:11-17.[Abstract/Free Full Text]
  2. Dumus, J. L., C. Van Delden, K. Perron, and T. Kohler. 2006. Analysis of antibiotic resistance gene expression in Pseudomonas aeruginosa by quantitative real-time-PCR. FEMS Microbiol. Lett. 254:217-225.[CrossRef][Medline]
  3. Giraud, E., A. Cloeckaert, D. Kerboeuf, and E. Chaslus-Dancla. 2000. Evidence for active efflux as the primary mechanism of resistance to ciprofloxacin in Salmonella enterica serovar Typhimurium. Antimicrob. Agents Chemother. 44:1223-1228.[Abstract/Free Full Text]
  4. Kern, W. V., M. Oethinger, A. S. Jellen-Ritter, and S. B. Levy. 2000. Non-target gene mutations in the development of fluoroquinolone resistance in Escherichia coli. Antimicrob. Agents Chemother. 44:814-820.[Abstract/Free Full Text]
  5. Llanes, C., D. Hocquet, C. Vogne, D. Ali-Baitich, C. Neuwirth, and P. Plesiat. 2004. Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrob. Agents Chemother. 48:1797-1802.[Abstract/Free Full Text]
  6. Miyamae, S., H. Nikaido, Y. Tanaka, and F. Yoshimura. 1998. Active efflux of norfloxacin by Bacteroides fragilis. Antimicrob. Agents Chemother. 42:2119-2121.[Abstract/Free Full Text]
  7. Pumbwe, L., O. Ueda, F. Yoshimura, A. Chang, R. L. Smith, and H. M. Wexler. 2006. Bacteroides fragilis BmeABC efflux systems additively confer intrinsic antimicrobial resistance. J. Antimicrob. Chemother. 58:37-46.[Abstract/Free Full Text]
  8. Pumbwe, L., A. Chang, R. L. Smith, and H. M. Wexler. Clinical significance of overexpression of multiple RND efflux pumps in isolates of Bacteroides fragilis. J. Antimicrob. Chemother., in press.
  9. Ricci, V., M. L. Peterson, J. C. Rotschafer, H. Wexler, and L. J. Piddock. 2004. Role of topoisomerase mutations and efflux in fluoroquinolone resistance of Bacteroides fragilis clinical isolates and laboratory mutants. Antimicrob. Agents Chemother. 48:1344-1346.[Abstract/Free Full Text]
  10. Roychoudhury, S., T. L. Twinem, K. M. Makin, M. A. Nieaber, C. Li, T. W. Morris, B. Ledoussai, and C. E. Catrenich. 2001. Staphylococcus aureus mutants isolated via exposure to nonfluorinated quinolones: detection of known and unique mutations. Antimicrob. Agents Chemother. 45:3422-3426.[Abstract/Free Full Text]
  11. Sanchez, P., E. Moreno, and J. L. Martinez. 2005. The biocide triclosan selects Stenotrophomonas maltophilia mutants that overproduce the SmeDEF multidrug efflux pump. Antimicrob. Agents Chemother. 49:781-782.[Abstract/Free Full Text]
  12. Sidhu, M. S., S. Langsrud, and A. Holck. 2001. Disinfectant and antibiotic resistance of lactic acid bacteria isolated from the food industry. Microb. Drug Resist. 7:73-83.[CrossRef][Medline]
  13. Stintzi, A., D. Marlow, K. Palyada, H. Panciera, L. Whiteworth, and C. Clarke. 2005. Use of genome-wide expression profiling and mutagenesis to study the intestinal lifestyle of Campylobacter jejuni. Infect. Immun. 73:1797-1810.[Abstract/Free Full Text]
  14. Ueda, O., H. M. Wexler, K. Hirai, Y. Shibata, F. Yoshimura, and S. Fujimura. 2005. Sixteen homologs of the mex-type multidrug resistance efflux pump in Bacteroides fragilis. Antimicrob. Agents Chemother. 49:2807-2815.[Abstract/Free Full Text]
  15. Wexler, H. M., E. Molitoris, F. Jashnian, and S. M. Finegold. 1991. Comparison of spiral gradient with conventional agar dilution for susceptibility testing of anaerobic bacteria. Antimicrob. Agents Chemother. 35:1196-1202.[Abstract/Free Full Text]
  16. Zhao, X., and K. Drlica. 2002. Restricting the selection of antibiotic-resistant mutant bacteria: measurement and potential use of the mutant selection window. J. Infect. Dis. 185:561-565.[CrossRef][Medline]

Antimicrobial Agents and Chemotherapy, September 2006, p. 3150-3153, Vol. 50, No. 9
0066-4804/06/$08.00+0     doi:10.1128/AAC.00141-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pumbwe, L.
Right arrow Articles by Wexler, H. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pumbwe, L.
Right arrow Articles by Wexler, H. M.

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS